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ABSTRACT
Objectives To estimate the cost of functional 
gastrointestinal disorders (FGIDs) and related signs 
and symptoms in infants to the third party payer and to 
parents.
Study design To estimate the cost of illness (COI) 
of infant FGIDs, a two-stage process was applied: a 
systematic literature review and a COI calculation. As no 
pertinent papers were found in the systematic literature 
review, a ‘de novo’ analysis was performed. For the latter, 
the potential costs for the third party payer (the National 
Health Service (NHS) in England) and for parents/carers 
for the treatment of FGIDs in infants were calculated, 
by using publicly available data. In constructing the 
calculation, estimates and assumptions (where necessary) 
were chosen to provide a lower bound (minimum) of the 
potential overall cost. In doing so, the interpretation of the 
calculation is that the true COI can be no lower than that 
estimated.
Results Our calculation estimated that the total costs 
of treating FGIDs in infants in England were at least 
£72.3 million per year in 2014/2015 of which £49.1 million 
was NHS expenditure on prescriptions, community care 
and hospital treatment. Parents incurred £23.2 million in 
costs through purchase of over the counter remedies.
Conclusions The total cost presented here is likely 
to be a significant underestimate as only lower bound 
estimates were used where applicable, and for example, 
costs of alternative therapies, inpatient treatments or 
diagnostic tests, and time off work by parents could not 
be adequately estimated and were omitted from the 
calculation. The number and kind of prescribed products 
and products sold over the counter to treat FGIDs suggest 
that there are gaps between treatment guidelines, which 
emphasise parental reassurance and nutritional advice, 
and their implementation.
InTROduCTIOn
Functional gastrointestinal disorders 
(FGIDs), according to Rome IV criteria, are 
defined as variable combinations of chronic 
or recurrent gastrointestinal (GI) signs and 
symptoms without obvious structural or 
biochemical alterations.1 Within the first year 
after birth, such symptoms can be observed in 
up to 50% of infants.2 3 
A recent meta-review reported that the 
worldwide prevalence of the three most 
common FGIDs in infants, infantile regurgi-
tation, colic and functional constipation, is 
approximately 30%, 20% and 15%, respec-
tively.4 In addition, many children may present 
with a combination of FGIDs and related 
signs and symptoms.3 4 Although considered 
mostly as benign conditions, FGIDs are a 
source of concern and frustration for families 
that may cause them to seek the advice from 
healthcare professionals (HCPs).3 4
Diagnostic criteria for FGIDs have been 
defined and are being continuously revised, 
and algorithms have been developed for their 
practical management by HCPs.1 4–6 These 
algorithms build on parental support, reas-
surance and nutritional advice as first-line 
therapy. Depending on the specific condition, 
The costs of functional gastrointestinal 
disorders and related signs and 
symptoms in infants: a systematic 
literature review and cost calculation 
for England
James Mahon,1 Carlos Lifschitz,2 Thomas Ludwig,3 Nikhil Thapar,4 Julie Glanville,1 
Mohamad Miqdady,5 Miguel Saps,6 Seng Hock Quak,7 Irene Lenoir Wijnkoop,8 
Mary Edwards,1 Hannah Wood,1 Hania Szajewska9
To cite: Mahon J, Lifschitz C, 
Ludwig T, et al.  The costs of 
functional gastrointestinal 
disorders and related signs 
and symptoms in infants: 
a systematic literature 
review and cost calculation 
for England. BMJ Open 
2017;7:e015594. doi:10.1136/
bmjopen-2016-015594
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2016- 
015594).
Received 15 December 2016
Revised 20 October 2017
Accepted 23 October 2017
For numbered affiliations see 
end of article.
Correspondence to
Dr Carlos Lifschitz;  
 carlos. lifschitz@ hospitalitaliano. 
org. ar
Research
Strengths and limitations of the study
 ► The cost calculation is focused on more recent 
studies and data to ensure currency and most recent 
practice are reflected in terms of care of FGIDs and 
related signs and symptoms.
 ► Where necessary, estimates and assumptions were 
always chosen to provide consistently a lower bound 
of the potential cost.
 ► The total cost presented here is likely to be a 
significant underestimate of the true cost as lower 
bound estimates were used where applicable, and 
several costs could not be adequately estimated and 
were omitted from the calculation.
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advice is given on issues including feeding frequency and 
volume as well as allergen avoidance in both breast and 
formula fed infants. Despite stringent diagnostic criteria 
and treatment recommendations, daily practices may 
broadly deviate from these and infants suffering from 
FGIDs and related signs and symptoms receive a large 
number of other treatments that are either contraindi-
cated or not substantiated scientifically.7
The aim of this study was to estimate the cost of FGIDs 
and related signs and symptoms in infants to the third 
party payer and to parents.
MeThOdS
The study employed a two-stage methodology to estimate 
the cost of illness (COI) of infant FGIDs, a systematic 
literature review and a COI calculation. Here, we report 
in detail on the latter.
Stage 1
A systematic literature review was undertaken to iden-
tify any studies published in or after 2005 that provided 
information on (a) the frequency and volume of reported 
treatments of FGIDs and related signs and symptoms 
(regardless of their effectiveness); (b) costs to third party 
payers and/or parents of infants with FGIDs and related 
signs and symptoms of prescribed treatments, over the 
counter (OTC) or home remedies, visits to HCPs and 
other providers of complementary and other forms of 
care, and changes in infant formula; (c) loss of income 
for parents/carers of infants with FGIDs and related signs 
and symptoms, or the specific symptom combinations 
described above, through inability to return to work, time 
taken off work and out of pocket costs.
Studies of infants <12 months old with colic, regurgi-
tation and/or functional constipation were eligible for 
inclusion if the underlying cause of illness was believed 
to be related to a FGID. Studies in preterm infants were 
excluded. The details of the review methods and protocol 
have been published in detail.8 Studies reporting data 
about treatments, signs and symptoms of FGIDs were 
considered separately to studies reporting direct and 
indirect costs.
Stage 2: COI calculation for one country
Since the systematic review identified no research on 
COI for any country, we performed a calculation for 
one country using evidence from stage 1 (the literature 
review) where appropriate, and from readily available 
data sources. England was chosen as an exemplar country 
due to the availability and quality of data on healthcare 
resource use, both publicly and privately, and the avail-
ability of these data in the English language.
Potential costs were considered for the third party 
payer (the National Health Service (NHS) in England) 
and for parents/carers. In constructing the calcula-
tion, estimates and assumptions (where necessary) were 
chosen to provide a lower bound (minimum) of the 
potential overall cost. In doing so, the interpretation of 
the calculation is that the true COI can be no lower than 
that estimated.
Publicly funded healthcare resource use
Prescription data
Potential medicinal remedies for infant FGIDs and special 
infant formulas were identified either through the system-
atic review or via clinical expert opinion. The prescribed 
items considered in the analysis with the number and 
costs of prescriptions made in England are available from 
the Health and Social Care Information Centre (HSCIC). 
Data were available for 2014/2015 and cover prescrip-
tions made in both primary and secondary care.
Although the prescription analysis is precise on the 
cost of medications and formula, the analysis is not clear 
in all cases about whether the medicine or formula was 
indicated specifically for infants with FGIDs or specifically 
for those aged <12 months. Therefore, we made some 
assumptions. We assumed the colic remedies would be 
for children <12 months of age. If colicky symptoms had 
not cleared by this time, further investigations would be 
undertaken and it is difficult to envisage situations where 
a persistently crying baby who appeared in pain would 
still be prescribed medications that must have proven 
ineffective up to that point. In addition, the Rome III 
criteria for infantile colic include only children who are 
<4 months, although it is not certain that this, in itself, 
would stop a general practitioner (GP) prescribing colic 
remedies once an infant reached that age.
For gastro-oesophageal reflux, the combination 
of aluminium hydroxide and magnesium carbonate 
(Gaviscon infant) is suitable up to 24 months of age. 
However, clinical advice and evidence from systematic 
reviews suggest that nearly all reflux and regurgitation 
would clear by the age of 12 months. Hence, we estimated 
that 90% of the Gaviscon infant would be prescribed to 
children <12 months.
Proton pump inhibitors (PPIs) have not been included 
in the analysis as these should only be used in diagnosed 
gastro-oesophageal reflux disease which is not a FGID. 
However, PIPs have been reported to be overprescribed 
by paediatricians in general, and more specifically for 
infantile colic, though these have been proven to be inef-
fective9 and have frequent side effects.10–12
For constipation, docusate sodium (Ducosol paediatric) 
is suitable for those up to the age of 12 years. Hence, we 
have divided the number of prescriptions and the cost by 
12 to provide an estimate of prescriptions to those <12 
months. Infant glycerol suppositories were also included, 
and we assumed that all prescriptions were for infants <12 
months, because a paediatric formulation is available for 
those >12 months. We considered prescriptions of lactu-
lose, but it was not possible to isolate a preparation just 
for infants and children. Most preparations for the treat-
ment of constipation are not recommended for those <12 
months of age even if, in practice, they may be used with 
infants.
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Primary and community care costs
From a community care perspective, an assumption was 
made that infants with infantile colic will require one 
extra home visit from a health visitor compared with 
babies without colic. Evidence suggests that the inci-
dence of infantile colic is between 10% and 40%.13 A 
National Institute of Health Research funded ongoing 
trial of supporting parents of infants with colic indi-
cates an incidence of one in five infants.14 Applying the 
1:5 figure to the 697 852 infants born live in England and 
Wales in 2015 means that approximately 140 000 infants 
in England experienced colic in that year.
Without data on the number of GP appointments, it has 
been assumed that as prescriptions will in most cases have 
been written by a GP, the number of appointments must, 
as a minimum, be equal to the number of prescriptions 
written. Although it is possible that more than one item 
could have been written at the same time, it was consid-
ered that in routine clinical practice for infantile colic, 
only one medicine would have been tried at any one 
time. Follow-up consultations have not been included in 
the analysis nor have any consultations that resulted in no 
prescription. As such, the estimate that GP consultations 
will be equal to the number of prescriptions will result 
in a conservative estimate of the true impact of GP time 
spent dealing with FGIDs.
Hospital care
Data on hospital care and activity are collected in England 
by each hospital and collated each year as the Hospital 
Episode Statistics (HES) dataset, available through the 
HSCIC. This dataset contains information on all accident 
and emergency (A&E) and outpatient attendances and 
admitted patient care in England.
The admitted patient care dataset provides informa-
tion on all planned and unplanned hospital admissions, 
including those seen as day cases. Planned admissions 
are usually for surgical procedures. Unplanned admis-
sions can be for emergency operations but can also be 
for patients staying in hospital for observation. Data are 
available on the primary International Classification of 
Diseases 10th Revision (ICD-10) diagnostic code of the 
admitted patient as well as the age of the patient. We 
received expert advice on the ICD-10 codes that would 
be used exclusively for infant FGIDs. We excluded codes 
that could also be used for other conditions, resulting in 
our estimate being a lower bound of actual admissions 
for FGIDs.
HES collates data on all patients who present at hospital 
emergency rooms (A&E in the UK). Data are not as 
detailed as those for admitted patient care, although age 
is recorded and along with a broad diagnosis group, but 
no ICD-10 code. Data by age and diagnosis jointly are not 
readily available.
Data are available from HES on outpatient appoint-
ments. Outpatient appointments in the UK usually relate 
to appointments with hospital-based consultants or diag-
nostic professionals, or in some cases to receive a simple 
treatment that does not require a hospital bed. Outpatient 
appointments are, in almost all cases, made through GP 
referral. A patient in England cannot in most cases access 
specialist treatment or diagnostic procedures without a 
GP referral unless they pay privately. Outpatient data are 
available by ICD-10 code, but not routinely broken down 
by age.
OTC colic remedies and special infant formulas
Data were provided by IRi (Information Resources, INC) 
on OTC sales of colic remedies, simethicone, lactase, 




The full review results are presented in a supplement 
to this manuscript (online supplementary file). In total, 
12 364 records were identified from database searching 
and 78 from additional resources. After the steps of 
duplicate removal, title, abstract and full text screen, 
31 studies were identified that provided data about treat-
ments, signs and symptoms of FGID in infants. Three 
further studies provided additional data on young chil-
dren in the USA.15–17 Twenty-six of the 31 eligible studies 
were randomised controlled trials and 5 were case series.8 
Almost half (15) of these studies were undertaken in 
Europe18–32 (including 3 in the UK).30–32 Four studies 
were conducted in the USA,33–36 three in Australia,37–39 
three in Turkey40–42 and one each in Brazil,43 Canada,44 
China,45 Iran,46 Israel12 and Nigeria.47 Twenty-nine studies 
included infants with infantile colic and two studies 
included infants with constipation. Several different inter-
ventions were addressed in the eligible studies. We could 
not identify any study that addressed the whole spectrum 
of costs of treating FGID in infants.
Stage 2: COI calculation for england
Prescription data
Medicines or formulas prescribed in England to infants 
are fully covered by the NHS. A full list of the prescribed 
items considered, the number of prescriptions and the 
associated cost is shown in table 1.
We estimated the total number of prescriptions of 
colic and FGID medications for infants <12 months in 
2014/2015 to be 521 000, at a cost of £5.8 million and 
the total number of prescriptions of colic and antireflux 
formulas to be 58 000 at a cost of £0.9 million.
Primary and community care costs
We estimated that the average time for a home visit, 
including travel, would be 30 min, with a unit cost per half 
hour of £2548 giving a cost of £3.5 million.
Data from table 1 for colic and FGID medicines and 
formulas suggested a total of 578 000 prescriptions. At a 
cost of £45 per 11.7 min appointment, this would equate 
to a cost to the NHS of £26.0 million.48 
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Table 2 Number of admissions and mean length of stay for 








k21.9 Reflux 6717 1
p92.1 Regurgitation and 
rumination in newborn
136 1
f98.2 Feeding disorder of 
infancy and childhood
4 11
r11.1 Vomiting 4313 2




k59.1 Functional diarrhoea 5 6
r68.1 Excessive crying/fussy 
infant
1355 1
r14 Flatulence and related 
conditions
297 2
FGID, functional gastrointestinal disorder; ICD-10, International 
Classification of Diseases 10th Revision.
Table 1 Prescription analysis 2014/2015
Type of solution Sum of items (thousands) Cost £ (millions)
Medicinal 521.2 5.8
Colic 115.1 1.1
  Colief_Infant Dps 64.7 0.9
  Dentinox_Infant Colic Dps 3.1 <0.1
  Infacol_Susp 40 mg/mL S/F 47.1 0.2
  Nurse Harveys_Gripe Mix <0.1 <0.1
  Woodward’s_Gripe Water 0.2 <0.1
Constipation 24.8 <0.1
  Glycerol Suppository Infants (1 g) 23.9 <0.1
Docusol_Paed Soln 12.5 mg/5 ml S/F (1/12 of total prescriptions) 0.9 <0.1
Reflux and regurgitation 381.4 4.7
Gaviscon Infant_Sach 2 g (dual pack) S/F (9/10 of total prescriptions) 381.4 4.7
Colic and regurgitation formulas 58.8 0.9
  Reflux and regurgitation 55.8 0.8
  Colic 3.0 0.1
Grand total 580.0 6.7
Hospital care: admitted patient care
The total number of admissions for each of the ICD-10 
diagnosis codes for FGIDs or colic, with the length of stay 
included in the analysis, are shown in table 2.
A total of 16 183 infants were admitted to acute hospi-
tals in 2014/2015 in England due to FGIDs amounting 
to 25 800 bed days. The cost to the NHS of a day in a 
hospital bed in 2014/2015 was £359.13.49 The total cost of 
the admitted patient care was therefore £9.3 million. This 
cost is only for bed days and does not include the cost of 
any diagnostic procedures.
Hospital care: A&E visits
The number of A&E attendances for children <12 months 
of age was 483 000 in 2014/2015 and the percentage of all 
attendances for all ages for all GI conditions was 5.7%.50 
We estimated the number of attendances due to GI condi-
tions in infants aged <1 year by assuming that the propor-
tion of attendances due to GI conditions is the same 
across age groups. Evidence from the USA identified in 
the literature review suggested that 9.4% of all emergency 
department visits in the USA due to constipation were in 
those aged <12 months.16 If a similar pattern is seen in 
England and for all FGIDs, then this means that the esti-
mated attendances we have calculated are likely to be a 
significant underestimate.
The reference cost of a NHS A&E visit in 2014/2015 
was £132.49 So the total cost of all visits for infants in 
2014/2015 was £63.7 million. If all these visits by infants 
were due to FGIDs then this is the upper bound of what 
the cost of A&E services due to FGIDs could be. If the 
percentage attending A&E due to GI conditions is the 
same regardless of age, this suggests that the cost of these 
infant visits is no higher than £3.6 million.
Hospital care: outpatient data
The total number of outpatient appointments for the 
conditions of interest in 2014/2015 was very small and 
were in single figures in some cases. For the two condi-
tions with the highest number of appointments—consti-
pation and reflux—there were 4000 episodes for all ages. 
Therefore, the number of appointments for children 
<1 year of age would potentially be insignificant, from 
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Table 3 Summary of costs of colic/FGID in England 
2014/2015
Cost area Value (million)
Prescriptions of colic/reflux/constipation 
medicines
£5.8
Prescriptions of colic/reflux/constipation 
formulas
£0.9
Health visitor appointments £3.5
GP appointments (colic/reflux/constipation 
medicines and formula)
£26.0
Admitted patient care £9.3
A&E visits £3.6
OTC colic medicines £13.6
OTC antiregurgitation formulas £9.6
Total costs £72.3
A&E, accident and emergency; FGID, functional gastrointestinal 
disorder; GP, general practitioner; OTC, over the counter.
a cost perspective. However, in 95.5% of outpatient 
appointments, the condition is recorded as unknown or 
unspecified. Costs associated with outpatient care were 
excluded from the analysis because we were unable to 
isolate the appointments from the dataset. Given there 
were 85.6 m outpatient appointments in England in 
2014/2015, if only a small percentage of these were for 
infants with FGIDs, the total costs would be substantial. 
The exclusion of these appointments from the analysis is, 
therefore, a further conservative element of the overall 
calculation.
Alternative therapies
The literature review highlighted that a range of alterna-
tive therapies, particularly for infantile colic, had been 
considered across many countries. Such therapies include 
chiropractic services, physiotherapy, homoeopathy, 
osteopathy and acupuncture.24 27 28 30 31 No data were 
identified in the literature on the scale of use of these 
therapies. We contacted professional associations and 
regulatory bodies associated with each therapy to request 
any data they might hold on this issue. However, none 
were able to provide information for the analysis. The 
costs of these approaches are therefore not stated, which 
constitutes an underestimate of the real costs.
OTC colic remedies and special infant formulas
The total expenditure on colic remedies was £13.6 million 
and on antiregurgitation formulas was £9.6 million.
Estimated total cost infant FGIDs in England
Combining the different aspects of publicly funded and 
parental out of pocket expenditure on infant FGIDs 
described above, we reached an overall estimate of the 
COI of the conditions in England in 2014/2015. This is 
summarised in table 3. In total, the cost is estimated to 
have been £72.3 million.
dISCuSSIOn
There is compelling evidence of discrepancies between 
the guidelines for the diagnosis and treatment of FGIDs, 
what physicians recommend and what parents may do. 
Our systematic literature review reports a multitude of 
different treatments and approaches to manage infant 
FGIDs that are used or have been trialled. Those reported 
interventions may still represent only a fraction of the 
remedies that are being used on a daily basis. It is outside 
the scope of this review to evaluate the efficacy of any 
intervention mentioned here, although for some OTC 
remedies, it appears that tolerance and safety data from 
clinical studies are lacking.
We hypothesised that the management of FGIDs is 
associated with considerable expense and, in the absence 
of any complete COI dataset identified in the systematic 
literature review, we chose England as the focus of a COI 
calculation because of the availability and quality of data 
on public and private healthcare resource use.
Medicines or formulas prescribed in England to infants 
with FGIDs are free at the point of consumption: the 
entire cost is borne by the NHS. The prescribed items 
considered in this analysis, with the number and costs of 
prescriptions made in England, are available from the 
HSCIC. The latest data available are from 2014 to 2015 
and cover prescriptions made in both primary and 
secondary care. However, the taxpayer does not meet all 
the costs of healthcare in England. Most alternative ther-
apies are not provided free of charge and medications 
that do not require a prescription can be purchased at a 
pharmacy.
Our analysis has shown that the cost of FGIDs is substan-
tial, costing a minimum of £72.3 million in England 
in 2014/2015 (£50 million to the NHS). This estimate 
is likely to be significantly higher in reality as we have 
adopted a conservative approach in our estimates.
Expenditure per capita on healthcare in England is 
among the lowest of all developed countries.51 If this is 
the case for all age groups, then it would suggest that the 
estimate for England is at the lower end compared with 
expenditure in other developed countries for infants with 
FGIDs. Regardless, FGIDs are costly, both to parents and 
to the NHS in England, with substantial expenditure on 
treatments for which there is limited or no evidence of 
efficacy.
Our calculations are conservative both in the assump-
tions on which they are based and the costs which have 
been excluded. The latter include:
1. Alternative therapies.
2. Diagnostic or treatment costs for admitted infants
3. Outpatient consultations
4. PIPs.
5. Days taken off work by parents or carers (absentee-
ism).
6. Reduced productivity of parents at work (presentee-
ism).
7. Costs associated with side effects from inappropriate 
interventions.
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8. Prescriptions of constipation remedies such as lactu-
lose.
9. Prescriptions and OTC purchases of antiallergy and 
comfort formulas for infants who actually have an 
FGID.
These exclusions are both a strength and a limitation of 
the analysis. The exclusions provide confidence that the 
estimated cost is a true lower bound of the actual cost, but 
they result in an estimate that, by design, is not the true 
cost. The exclusions also indicate areas where further 
research is required. The total cost presented here is 
likely to be a significant underestimate of the true cost as 
lower bound estimates were used where applicable, and 
several costs could not be adequately estimated and were 
omitted from the calculation. Where necessary, estimates 
and assumptions were chosen to provide consistently a 
lower bound of the potential cost.
We estimated that the total yearly cost of therapies for 
FGIDs in infants in England was £72.3 million excluding 
antiallergy formulas. Records indicate that there are 
approximately 700 000 newborns per year. If 30% of these 
infants experienced FGIDs that required some kind of 
treatment, 210 000 infants per year would be affected. 
Dividing the total costs per year by the number of affected 
infants, we estimate a cost of £348 per infant in the first 
year after birth.
It is likely that most of the care of infants for FGIDs 
is met in the primary and community setting and this is 
borne out by the estimates. However, our estimates about 
the time spent by health visitors were based on little actual 
data on resource use but are, we consider, conservative.
It is not possible to determine whether all OTC medi-
cations purchased were recommended by a physician, 
pharmacist or other HCP. It was, however, reported in 
another study conducted in six countries that overall 17% 
of the paediatric prescriptions were for herbal remedies 
and 15% were for homoeopathic preparations.52
In conclusion, we found that FGIDs in infants generate 
substantial expense for parents and the healthcare 
system. Our estimate is likely to be lower than the real 
cost because of missing data and evidence.
The number and type of products sold to treat FGIDs 
suggested that some physicians do not follow treatment 
guidelines. Some infants are being medicated unneces-
sarily, which is potentially detrimental to patient health 
outcomes and definitely a wasted cost, either to the 
taxpayer or to parents. This may be the consequence of 
parental demands, but may also be a gap on the provi-
sion of parental reassurance. These findings support the 
impression of those co-authors who are paediatric gastro-
enterologists practising in different parts of the world 
(CL, NT, MM, MS, SHQ, HS) who see in consultation 
infants with FGIDs who frequently have been treated not 
in accordance to guidelines.
Further research is required to understand why some 
physicians are choosing to medicate and what strategies 
could be adopted such that doctors and parents can 
manage symptoms by following clinical guidelines without 
resorting to costly remedies and treatments with limited 
or no evidence on their effectiveness. The potential cost 
savings and improved health outcomes are significant if 
such strategies and options could be put in place.
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